# DDP ip Combined With AG in PDAC With Peritoneal Metastasis

> **NCT05222204** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 91 (actual)

## Conditions studied

- Pancreatic Neoplasm

## Interventions

- **DRUG:** intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel

## Key facts

- **NCT ID:** NCT05222204
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-15
- **Primary completion:** 2024-07-08
- **Final completion:** 2024-12-12
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222204, "DDP ip Combined With AG in PDAC With Peritoneal Metastasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05222204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*